<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03833830</url>
  </required_header>
  <id_info>
    <org_study_id>OCTA 2018-02043</org_study_id>
    <nct_id>NCT03833830</nct_id>
  </id_info>
  <brief_title>Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment</brief_title>
  <official_title>A Cross Sectional Study Assessing the Perifoveal and Peripapillar Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment - Pilotstudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Katja Hatz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cenaug Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vista Klinik</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neovascular age-related macular degeneration (nAMD) is characterized by the abnormal growth&#xD;
      of blood vessels from the choroid into the subretinal space which leads to sub- and&#xD;
      intraretinal fluid accumulation, hemorrhages and subretinal fibrosis with progressive loss of&#xD;
      central vision. Intravitreal anti-VEGF treatment is the standard of care. Intravitreal&#xD;
      anti-VEGF application might temporarily increase intraocular pressure due to a volume effect.&#xD;
      It remains unclear if repeated injections might have an impact on retinal capillary&#xD;
      perfusion. Therefore this study aims to investigate the vascular microcirculation differences&#xD;
      between patients who received longterm intravitreal Anti-VEGF treatment and patients who&#xD;
      recently started Anti-VEGF treatment using Optical Coherence tomography Angiography (OCTA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main outcome parameters are:&#xD;
&#xD;
        -  Vessel Perfusion Area (%) of central ETDRS subfields and peripapillar region as&#xD;
           evaluated by OCTA (single measurement)&#xD;
&#xD;
        -  Blood flux index(*) of central ETDRS subfields and peripapillar region as evaluated by&#xD;
           OCTA (single measurement).&#xD;
&#xD;
        -  Peripapillary and perifoveal retinal nerve fiber layer (RNFL) thickness (µm) as&#xD;
           evaluated by OCT (single measurement)&#xD;
&#xD;
        -  Intraocular pressure (IOP) (mmHg) (single measurement at study visit) and mean&#xD;
           intraocular pressure during anti-VEGF treatment period (evaluated as mean of all&#xD;
           retrospectively available IOP measures from the beginning of treatment, mmHg)&#xD;
&#xD;
      (*)Blood flux index is automatically calculated by ARI Network as the mean flow intensity in&#xD;
      the vessel area, where the blood flow signal was normalized to 0 to 1 by dividing by the full&#xD;
      dynamic range of blood flow signal intensity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Actual">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 2, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vessel Perfusion Area (%) and Flux index* of central ETDRS subfields and peripapillary region (single measurements at study visit), respectively, in both groups</measure>
    <time_frame>baseline V0</time_frame>
    <description>in both groups (longterm treatment group ( ≥20 intravitreal injections) and shortterm treatment group (&lt;5 intravitreal injections).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripapillary and perifoveal retinal nerve fiber layer (RNFL) thickness (µm) as evaluated by OCT (single measurement at study visit)</measure>
    <time_frame>baseline V0</time_frame>
    <description>in both groups (longterm treatment group ( ≥20 intravitreal injections) and shortterm treatment group (&lt;5 intravitreal injections).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure (IOP) (mmHg) (single measurement at study visit) and mean intraocular pressure during anti-VEGF treatment period (evaluated as mean of all retrospectively available IOP measures from the beginning of treatment, mmHg)</measure>
    <time_frame>baseline V0</time_frame>
    <description>in both groups (longterm treatment group ( ≥20 intravitreal injections) and shortterm treatment group (&lt;5 intravitreal injections).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>baseline V0</time_frame>
    <description>weight meassurements in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height</measure>
    <time_frame>baseline V0</time_frame>
    <description>height meassurements in cm</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>longterm treatment group</arm_group_label>
    <description>previous treatment (before Optical Coherence Tomography angiography (OCTA)) &gt;20 injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>shortterm treatment group</arm_group_label>
    <description>previous treatment (before Optical Coherence Tomography angiography (OCTA)) &lt; 5 injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography angiography (OCTA)</intervention_name>
    <description>There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group &gt;20 injections and shortterm treatment group &lt; 5 injections).</description>
    <arm_group_label>longterm treatment group</arm_group_label>
    <arm_group_label>shortterm treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive recruitment. All patients from Vista Klinik attending the retina outpatient&#xD;
        clinic, who fulfil the in- and exclusion criteria, will be offered the participation in the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for participation, patients will be required to&#xD;
&#xD;
          -  have been treated for sub- or juxtafoveal CNV due to nAMD with anti-VEGF intravitreal&#xD;
             injections either for at least 20 times (longterm treatment eyes) or &lt;5 times&#xD;
             (shortterm treatment eyes).&#xD;
&#xD;
          -  give written consent to participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosis of glaucoma/ocular hypertension at baseline of anti-VEGF treatment&#xD;
&#xD;
               -  history of retinal vascular disorders like diabetic retinopathy, retinal&#xD;
                  vein/arterial occlusive disease, uveitis etc.&#xD;
&#xD;
               -  history of papillary disease which might interfere with interpretation of&#xD;
                  peripapillary OCT/OCTA evaluation such as severe tilted disc, parapapillar CNV,&#xD;
                  papillar drusen, optic nerve neuritis, papillar edema etc.&#xD;
&#xD;
               -  inability to perform OCTA examination of sufficient quality.&#xD;
&#xD;
               -  history of any side effects of Tropicamide eye drops&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katja Hatz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vista Klinik Binningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vista Klinik</name>
      <address>
        <city>Binningen</city>
        <state>Baselland</state>
        <zip>4102</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vista Klinik</investigator_affiliation>
    <investigator_full_name>Dr. med. Katja Hatz</investigator_full_name>
    <investigator_title>Head of medical retina department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>if necessary on request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

